Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie W Lees

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Nature|June 29, 2017
Fine-mapping inflammatory bowel disease loci to single-variant resolutionHailiang Huang, Ming Fang, Luke Jostins, et al.
Lancet (London, England)|October 23, 2015
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association studyIsabelle Cleynen, Gabrielle Boucher, Luke Jostins, et al.
Wellcome Open Research|May 31, 2022
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data ReportAnna Rowan, Chris Bates, William Hulme, et al.
The Lancet. Rheumatology|June 14, 2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformBrian MacKenna, Nicholas A Kennedy, Amir Mehrkar, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.
Nature|June 29, 2017
Fine-mapping inflammatory bowel disease loci to single-variant resolutionHailiang Huang, Ming Fang, Luke Jostins, et al.
Lancet (London, England)|October 23, 2015
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association studyIsabelle Cleynen, Gabrielle Boucher, Luke Jostins, et al.
Wellcome Open Research|May 31, 2022
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data ReportAnna Rowan, Chris Bates, William Hulme, et al.
The Lancet. Rheumatology|June 14, 2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformBrian MacKenna, Nicholas A Kennedy, Amir Mehrkar, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
BMJ Open|April 17, 2024
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicineNicola J Wyatt, Hannah Watson, Carl A Anderson, et al.
Pageof 10